MELANOMA CRITICAL DEBATES - PART 9 pps
MELANOMA CRITICAL DEBATES - PART 9 pps
... Oncol 199 9; 17: 3313–23. 12 Baselga J. New horizons: gene therapy for cancer. Anticancer Drugs 199 9; 10 (Suppl. 1): 39 42. 13 McCormick F. Cancer therapy based on p53. Cancer J Sci Am 199 9; 5 (3): ... department in France. Dermatology 199 5; 191 (3): 199 –203. 10 Sylaidis P, et al. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg 199 7; 50 (5): 3 49 53. treatment, the...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 4 pps
... of melanomas and dysplastic nevis. Dermatology 199 8; 196 : 299 –304. 27 Piccolo D, Smolle J, Wolf IH, et al. Face- to-face diagnosis vs. telediagnosis of pigmented skin tumors. Arch Dermatol 199 9; ... Dermatol 199 9; 41: 7 49 56. 24 Andreassi L, Perotti R, Rubegni P, et al. Digital dermoscopy analysis for the differentiation of atypical nevi and early melanoma. Arch Dermatol 199 9; 135: 1...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 1 ppt
... cm. ISBN 0-6 3 2-0 577 2-6 1. Melanoma. I. Bishop, J. A. Newton (Julia A. Newton) II. Gore, Martin [DNLM: 1. Melanoma. QZ 200 C437 2001] RC280.M37 C48 2001 616 .99 ¢477—dc21 2001035202 ISBN 0-6 3 2-0 577 2-6 A ... malignant melanoma. Br Med J 198 6; 292 : 1555– 60. 13 Newton JA. et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 2 pdf
... 1.20–2 .98 * (583/608) Females: 1.45† 0 .99 –2.13 Sweden, 199 4 [3] 198 8 90 1.3‡ 0 .9 1.8 (400/640) Belgium, France, Germany, 199 4 [2] 199 1 92 0 .97 † 0.71–1.32 (420/447) Connecticut, 199 8 [23] 198 7– 89 1.13‡ 0.82–1.54 (624/512) *P ... 198 9 93 105/138 0.2 (0.40–0. 79) Ø Espinosa Spain 199 0 94 116/235 0.48 (0.34–0.71) Ø Arranz et al. [52] Autier et al. [53] Europe 199 1 92 418/438 1.50...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 3 pptx
... familial melanoma. Nat Genet 199 6; 12: 97 9. 18 Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma- prone families in France. Hum Mol Genet 199 8; 7: 2 09 16. 19 ... FEBS Lett 199 7; 418: 87 90 . 74 Stevenson C, Davies RJH. Photosensitisation of guanine-specific DNA damage by 2-phenylbenzimidazole and the sunscreen agent 2-phenyl- benzim...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 5 ppt
... malignant melanoma: review of 1086 patients. Br J Surg 199 1; 78: 1108–10. 12 MacKie R, Hunter JAA, Aitchison TC, et al. Cutaneous malignant melanoma, Scotland, 197 9– 89. Lancet 199 2; 3 39: 97 1–5. 13 ... Prevention of Malignant Melanoma. Basel: Karger, 199 6: 31–42. 23 Howell JB, Cockerell CJ. Melanoma self- examination day: Melanoma Monday, May 1, 199 5. J Am Acad Dermatol 199...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 6 pot
... Follow-up of patients with a thin melanoma. Br J Surg 199 9; 86: 6 19 21. 25 Kanzler MH. Initial evaluation of melanoma: don’t stop getting that chest X- ray Yet [letter]. Arch Dermatol 199 9; 135: ... (1.51–3 .99 mm). Cancer 198 5; 56: 413–8. 22 Rompel R, Garbe C, Buttner P et al. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 199 5;...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 7 ppt
... 20 69, 199 9. 42 Moon JH, Gailani S, Cooper. MR, et al. Comparison of the combination of 1, 3- bis(2-chloroethyl-1-nitrosurea (BCNU) and vincristine with two dose schedules of 5-( 3,3-dimethyl-1-triazino) ... – – Low-dose IFN 499 French trial + – 311 Austrian trial + – 99 Scottish trial – – 340 EORTC 18871/DKG-80 – – Stage III High-dose IFN 160 NCCTG – – 2 49 ECOG 1684 ++ 4 79 ECOG...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 8 pot
... Chemotherapy — 92 Lakhani 199 0 [ 59] 164 Chemotherapy — 4 — Sirott 199 3* [60] 284 Various 7.4 —— Creagan 199 0 [61] 191 Interferons 6.0 9 2 Barth 199 5* [62] 1521 Various 7.5 14 6 EORTC report 199 7 [55] Response ... Med 199 9; 1 89: 871–6. 61 Oiso M, Eura M, Katsura F, et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer...
Ngày tải lên: 09/08/2014, 15:20
MELANOMA CRITICAL DEBATES - PART 10 pptx
... III 198 –200, 199 high-dose 199 low-dose 199 –200 trials in stage II 200–1 g-interferon 197 , 233, 234, 243 interleukins IL-2 195 , 197 , 222, 238, 243 IL-4 243 IL-10 243 IL-12 243 in-transit melanoma ... 18–23 cutaneous melanoma 19 20, 20, 22 duration of exposure 21 ocular melanoma 20 avb3 integrin 240 intercellular adhesion molecule-1 (ICAM-1) 222 a-interferon (IFN-a) 195 , 197 , 1...
Ngày tải lên: 09/08/2014, 15:20